In addition, it has been reported that Drp1 promotes KRas-driven metabolic changes to drive pancreatic tumor growth and that the expression of dynamin-related protein 1 (Drp1) in epithelial ovarian cancer has a poor prognosis, suggesting that Drp1 may be used as a biomarker for malignant tumors [76,77]. This evidence concerns the gene DNM1L and cancer.